Introduction {#s1}
============

Non-small cell carcinoma that harbor an activating mutation in the epidermal growth factor receptor (EGFR) kinase domain are associated with sensitivity to tyrosine kinase inhibitor (TKIs) \[[@R01], [@R02]\]. On the other hand, mutation in Kirsten RAS (*KRAS*), which encodes a GTPase, downstream of EGFR pathway, is associated with primary resistance to TKIs \[[@R03]\]. The *KRAS* gene encodes the human cellular homolog of a transforming gene of the Kirsten rat sarcoma-2 virus \[[@R04]\]. EGFR mutations are more commonly found in tumors from patients who never smoked cigarettes \[[@R02]\], while *KRAS* mutations are present in those with significant tobacco exposure \[[@R03]\]. *KRAS* mutational analysis is critical for predicting anti-EGFR therapeutic response in lung adenocarcinoma. Sufficient and reliable tissue samples are essential for mutational analysis.

Needle core lung biopsies and cytology specimen are most often the first sample to be obtained for diagnosis of lung primary and work up advanced cases of lung cancers, respectively. Hence an ideal approach would be to perform molecular tests on cytology specimen or needle core biopsy to optimize treatment. Although *KRAS* mutational analysis has been performed using cytology specimen and needle core biopsies, most of these studies lack comparisons to resected specimen for validation \[[@R05]-[@R9]\]. Concordance between cytology and resected specimen for mutational analysis is unknown. Recently, Solomon et al compared core biopsies and corresponding surgical resection and showed that core biopsies can yield sufficient and reliable samples for *KRAS* mutation analysis \[[@R9]\].

The purpose of this study was to retrospectively compare the accuracy of cytology specimen or needle core biopsy obtained prior to resection with that or resected lung tumor specimen, the histologic gold standard, for *KRAS* mutational analysis.

Material and Method {#s2}
===================

This was a retrospective study and received exemption for IRB approval.

Surgical specimen {#s2a}
-----------------

Computer search at our institution from January 2001 to December 2008 yielded 22 lung adenocarcinoma resections that also had available cytology specimen or core needle biopsy of lung tumor prior to resection. Core biopsies of lung tumor were available in only 10 cases. Formalin-fixed paraffin embedded (FFPE) tissue block of resected tumor, and core biopsies were used for isolation and amplification of DNA. The percentages of tumor cells in the core biopsies and surgical resection specimen selected for molecular study ranged from 10% to 70%. Direct sequencing was applied to detect *KRAS* mutations in codon 12 and 13.

Cytology specimens {#s2b}
------------------

Seventeen cytology specimen including 8 FFPE cell blocks and 9 Diff Quik (DQ)-stained smears were available on 12 patients with lung adenocarcinoma who had also undergone surgical resection. Procedures that were performed on these 12 patients to procure cytology specimen included CT-guided FNA of lung tumor \[[@R08]\], Transbronchial FNA \[[@R03]\] and bronchial washing \[[@R01]\]. All the hematoxylin and eosin (H&E)-stained slides from the FFPE cell blocks were reviewed by the pathologist to quantify the tumor cells. The percentages of tumor cells in the specimen selected for molecular study ranged from 2 to 40%. In the samples where tumor cells were scanty, the percentage was determined by counting the cells in representative high power field. The tumor foci were marked on the H&E- stained slides obtained from the FFPE cell block and used as a guide to scrape the tumor cells from unstained slide. In the cases of direct smears, the DQ slides were marked and tumor cells were isolated using pin point isolation technique that resulted in precise isolation of tumor cells (greater than 90%).

Genomic DNA extraction {#s2c}
----------------------

Total DNA was extracted from FFPE sections and cytology stained smear slides using Zymo's Pinpoint Slide DNA Isolation System (Orange, CA). Sections of FFPE tissue were mounted on slides and upon a pathologic exam; areas of only tumor were outlined and collected using a scalpel. Cytology stained smear slides were placed in xylene for 3 - 6 days to float off coverslip and only stained tumor cells were collected using a needle using a needle under the microscope. DNAs from all samples were extracted per manufacturer's instructions.

COLD PCR {#s2d}
--------

DNAs extracted were tested by co-amplification-at-lower denaturation-temperature PCR (COLD PCR) based on a previously described method by Z Zuo et al \[[@R10]\]. Briefly, COLD PCR was performed in a 50 µL of reaction mixture containing 1 µL of extracted DNA, 0.2 µmoL/L each primer ([Table 1](#T1){ref-type="table"}), 250 µmoL/L of dNTP mix, 2.5 mmoL/L MgCl2, 1x PCR buffer, and 1U AmpliTaq Gold (Applied Biosystems, Carlsbad, CA). The reaction mixture was run as follows: 95 °C for 10 minutes, 10 cycles of 95 °C for 15 seconds, 57 °C for 30 seconds, 72 °C for 1 minute; 72 °C for 7 minutes, 95 °C for 2 minutes; 40 cycles of 95 °C for 15 seconds, 70 °C for 8 minutes, 80 °C for 3 seconds, 55 °C for 30 seconds, 72 °C for 1 minute on a GeneAMP PCR system 9700 (PE Applied Biosystems, Foster City, CA). A positive control with a known *KRAS* mutation and a negative control of non-template sample were included for each PCR. These PCR products were then electrophoresed on polyacrylamide Ready Gels of 10% TBE (Bio-Rad, Hercules, CA), stained with ethidium bromide and 1 band of 98 bp was expected.

###### Primer Used for COLD PCR

  Name              Sequence
  ----------------- ------------------------------
  \*KRAS-ZuoF^10^   5\'-TATAAACTTGTGGTAGTTGG-3\'
  \*KRAS-ZuoR^10^   5\'-ATTGTTGGATCATATTCGT-3\'

All Sequences Were Synthesized by Integrated DNA Technologies Inc. (Coralville, IA)

\*F for forward and R for reverse.

Purification and DNA Sequencing {#s2e}
-------------------------------

Centri-sep spin columns (Princeton Separations, Adelphia, NJ) were used to purify PCR products per manufacturer\'s instructions. Purified products were labeled for sequencing using BigDye Terminator version 1.1 cycle sequencing kit (Applied Biosystems, Foster City, CA) according to manufacturer's instructions. Products were then subjected to another centri-sep spin column purification for removal unincorporated dye labels and then run on an ABI 310 Genetic Analyzer running Sequencing Analysis Software version 5.2 (Applied Biosystems, Foster City, CA). Products were run in duplicates and with a positive control with a known *KRAS* mutation.

Results {#s3}
=======

The test results of *KRAS* mutation on 10 core biopsies and corresponding surgical resection specimen are shown in [Table 2](#T2){ref-type="table"}. *KRAS* mutations were detected in 7 out of 10 core biopsies and their corresponding resection specimen. In 3 cases, no mutation was detected in both core biopsy and resection specimen. Surgical biopsy specimen showed 100% concordance with the corresponding resection specimen.

###### Detection of *KRAS* Mutation in Needle Biopsies and Corresponding Surgical Resections

  Case ID   Biopsy   Surgical            Concordance                       
  --------- -------- ------------------- ------------- ------------------- -----
  1         30       G12V (G[T]{.ul}T)   50            G12V (G[T]{.ul}T)   Yes
  2         25       G12D (G[A]{.ul}T)   70            G12D (G[A]{.ul}T)   Yes
  3         40       G12C ([T]{.ul}GT)   40            G12C ([T]{.ul}GT)   Yes
  4         30       G12C ([T]{.ul}GT)   30            G12C ([T]{.ul}GT)   Yes
  5         30       No mutant           40            No mutant           Yes
  6         \< 10    G12S ([A]{.ul}GT)   70            G12S ([A]{.ul}GT)   Yes
  7         50       No mutant           60            No mutant           Yes
  8         40       G12A (G[C]{.ul}T)   30            12A (G[C]{.ul}T)    Yes
  9         50       No mutant           60            No mutant           Yes
  10        10       G12A (G[C]{.ul}T)   25            12A (G[C]{.ul}T)    Yes

The results of *KRAS* mutations tests on 8 FFPE cell block (cytology) specimen and the corresponding surgical resection cases were shown in [Table 3](#T3){ref-type="table"}. Status of *KRAS* mutation in 5 out of 8 (63%) cell blocks showed concordance with their corresponding surgical resection. However, *KRAS* mutation detected in 3 surgical resection specimen was not detectable in the corresponding cell blocks.

###### Detection of *KRAS* Mutation in Cytology Cell Blocks and Corresponding Surgical Resections

  Case ID   Cytology Cell Block   Surgical                 Concordance                       
  --------- --------------------- ------------------------ ------------- ------------------- -----
  1         \< 10                 G12V (G[T]{.ul}T)        50            G12V (G[T]{.ul}T)   Yes
  2         15                    G12C ([TG]{.ul}T)        40            G12C ([T]{.ul}GT)   Yes
  3         30                    G12D (G[A]{.ul}T)        60            G12D (G[A]{.ul}T)   Yes
  4         30                    G12V (G[T]{.ul}T)        60            G12V (G[T]{.ul}T)   Yes
  5         20                    No mutation detectable   35            G12C ([T]{.ul}GT)   No
  6         \< 2                  No mutation detectable   40            G12C ([T]{.ul}GT)   No
  7         2                     No mutation detectable   20            G12D (G[A]{.ul}T)   No
  8         60                    No mutation              60            No mutation         Yes

The results *KRAS* tests on 9 cytology smears and the corresponding resection specimen are shown in [Table 4](#T4){ref-type="table"} These 9 cytology smears included 3 cytology cases (Cytology case ID\# 5, 6, 7, [Table 3](#T3){ref-type="table"}) that were initially tested on cell block and did not correlate with the surgically resected tissue for *KRAS* mutation analysis. Eight of 9 cytology smears showed the same results as in the corresponding surgical resections including 3 mutants which were not detected in the corresponding cell blocks, with 89% concordance ([Fig. 1](#F1){ref-type="fig"}). *KRAS* mutation was detected in one cytology smear and was not detected in the resected surgical specimen.

![Example (case 6, [Table 3](#T3){ref-type="table"}) of DNA sequence (anti-sense) of KRAS mutation in cytologic smear and corresponding surgical section. KRAS mutation in code 12 (G12C) were identified in both cytologic and corresponding surgical specimen. Please note that mutant peak (C \> A) is higher in cytologic smear than in surgical resection.](wjon-02-275-g001){#F1}

###### Detection of *KRAS* Mutation in Cytology Smears and Corresponding Surgical Resections

  Case ID   Cytology Smear   Surgical               Concordance                        
  --------- ---------------- ---------------------- ------------- -------------------- -----
  1         N/A              No mutant              30            No mutant            Yes
  2         N/A              G12D (G[A]{.ul}T)      60            G12D (G[A]{.ul}T)    Yes
  3         N/A              G12D (G[A]{.ul}T)      30            G12D (G[A]{.ul}T)    Yes
  4         N/A              G12V (G[T]{.ul}T)      25            G12V (G[T]{.ul}T)    Yes
  5         N/A              G12C ([T]{.ul}GT)      35            G12C ([T]{.ul}GT)    Yes
  6         N/A              G12C ([T]{.ul}GT)      40            G12C ([T]{.ul}GT)    Yes
  7         N/A              G12D (G[A]{.ul}T)^2^   20            G12D (G[A]{.ul}T)    Yes
  8         N/A              G12D ( G[A]{.ul}T)     35            G12D ( G[A]{.ul}T)   Yes
  9         N/A              G12F ([TT]{.ul}T)      40            No mutation          No

^1^Not applicable since the tumor cells are isolated on smears with pinpoint technique; ^2^Small mutation peak at code 13 (GAC) as well

Discussion {#s4}
==========

With advent of novel treatment modality for NSCLC, molecular testing for EGFR and *KRAS* mutations is of increasing clinical importance in daily clinical practice. Evaluation of *KRAS* mutational status is critical because *KRAS* is not only an important downstream step of EGFR but also its mutations is related with resistance to EGFR-targeted therapy \[[@R11]-[@R13]\].

Image guided lung core biopsy or cytology specimen (CT-guided FNA, transbronchial FNA and bronchial brushing and washings) represent minimally invasive procedures for histologic diagnosis staging of lung adenocarcinoma. Comparison of adequacy of these procedures with adequacy of surgically resected specimen, the histologic reference standard, for mutational analysis of tumors of the lung has not been sufficiently investigated. Hence it is uncertain if reliable material can be procured from these procedures for mutational analysis.

In our study we demonstrated 100% agreement between image guided core needle biopsy and surgical resection specimen for *KRAS* mutational analysis. Similar results were shown Solomon et al with an 89% (16 of 18 cases) concordance for mutational analysis between the two types of specimen (image guided core needle biopsy versus surgical resection specimen) \[[@R9]\]. Lack of concordance in 2 (11%) of their cases was attributed to unsatisfactory image core needle biopsy specimen.

Studies describing the use of routinely collected cytology specimen, such as smears or cell blocks for *KRAS* mutational analysis of lung tumors are few. Rekhtman et al demonstrated that of the 128 cytologic specimen comprising of cell blocks 98% were suitable for molecular analysis and revealed *KRAS* mutations in 25 (20%) cases \[[@R06]\]. Recently Billah et al also showed that *KRAS* mutation in 23.6% (41 of 174) of cytologic specimen of lung tumor \[[@R07]\]. Feasibility of fine needle cytological aspirates for *KRAS* mutational analysis has also been shown by Schuurbiers et al \[[@R08]\]. However, none of these studies have compared the *KRAS* mutational result of cytology specimen with resected lung tumor. Lack of such comparison raises a possibility that in cases with lack of detection of *KRAS* mutation on cytology specimen may be secondary to tumor heterogeneity and may represent a false negative.

In order to ensure the reliability of cytology samples for mutational analysis we paired both cell blocks and cytology smears with corresponding resected lung tumor tissue for *KRAS* mutational analysis. In our study we demonstrated 63% agreement in results for mutational analysis between cell blocks and surgically resected specimen. Lack of correlation in 3 (37%) of our cases could be attributed to low cellularity in cell blocks (2% tumor cells) in 2 cases and failure to retrieve DNA in one case. However, when we used the cytology smears of corresponding cell block cases, we achieved a 100% agreement between cytology specimen and resected lung tumor for *KRAS* mutational analysis.

Comparison of cytology smears with resected tumor specimen showed that 89% (8 out of 9) were in agreement for *KRAS* mutational analysis. Interestingly, *KRAS* mutation (G12F) was detected in one cytology smear (case 9, [Table 3](#T3){ref-type="table"}) that was not noted in resected lung tumor. This may be attributed to tumor heterogeneity and/or different percentage of tumor cells. The ease with which tumor cells can be selectively scraped from the smears reduces normal cell contamination during DNA extraction and therefore enhances tumor cell population as opposed to microdissection of tumor in FFPE where the stromal cells and inflammatory cells may reduce the percentage of tumor cells. Percentage of tumor cells isolated in the discrepant case was greater than 90% in cytology smear versus 40% in the resected lung tumor. G12F with two mutations in code 12 (GGT \> TTT) is a rare variant of *KRAS* mutations, and has been previously reported \[[@R14]\].

Our study is limited by its small sample size. Nevertheless, excellent agreement with resected lung tumor specimen suggests that core biopsies as well as cytologic specimen derived from CT-guided, endoscopic bronchial ultrasound guided, trans-bronchial FNAs and body fluids yield adequate and reliable material for *KRAS* mutational analysis. Our data also shows that in cases of low cellularity in tumor cell block material, cytology smears are better than cell block for *KRAS* mutational analysis.

The disadvantage of use of direct smear for molecular studies is that diagnostic material is not recoverable once it is used for molecular study. If cytology smears are to be used for DNA retrieval, it is necessary to ensure there are enough slides available so that the entire diagnostic material with morphologic details is not lost.

In summary, we have demonstrated that the standard molecular technique of detecting *KRAS* mutation in lung tumor can be adequately applied on cytology specimen and core needle biopsies. *KRAS* mutation analysis on cytology specimen and core needle biopsy is highly accurate and comparable with that of resected lung tumor. The need for more invasive procedures to obtain sufficient tumor tissue for molecular test could thus be obviated. Presence of *KRAS* mutation of cytology smears and lack of detection in corresponding resected tumor in one of our cases suggests that cytology smears may be more suitable and sensitive source for *KRAS* mutational analysis. However more validation studies comparing mutational analysis on cytology smears and resected lung tumor on larger scale are needed.
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